Shares of Moderna Inc MRNA are trading lower Wednesday morning, taking a breather following a 170% surge over the trailing ...

Moderna (MRNA) stock climbed 3.6% on melanoma vaccine trial success and COVID approval, but analysts remain cautious with $80 ...

The company may be on track to its next product.

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher.

Prior to the melanoma outcome, indicators included an enrolled trial, a partner covering half the expenses, and a market that ...

Shares of Moderna rocketed by 93% to around $121.90 on Wednesday, pacing what would be the stock’s best-ever trading session after surging by more than 100% in premarket trading. That came after ...

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and ...

A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies recently ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...

Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

The company says a trial met its goal to prevent melanoma recurrence.